Type 1 Diabetes and Celltex Stem Cell Therapy

What is Type 1 Diabetes

Type 1 diabetes, previously known as juvenile diabetes due to its prevalence in children and young adults, is a chronic condition in which the body does not naturally produce insulin (Type 2 diabetes, the much more common form, happens when the body is resistant to insulin or produces scarce amounts). Out of those affected with diabetes, only five percent have type 1.

Patients with the condition often experience increased hunger and thirst, dry mouth, nausea, vomiting, stomach pain, frequent urination, abnormal weight loss, and extreme fatigue.

Insulin is a hormone that transmits glucose from the bloodstream into cells, and our bodies need it to function properly. If insulin levels are monitored and blood sugar is kept within a controlled range, the condition can be combatted to allow even the youngest child to live a long and healthy life.

How can Celltex stem cell therapy help?

Given the immunomodulatory phenotype of Mesenchymal Stem Cells (MSCs), there is potential (especially in patients with early diagnosis) that MSCs could help reduce beta cell (β-cell) death and thereby preserve healthy β-cells in the pancreas. Co-administration of MSCs with β-cells could also help to reduce graft rejection by the host. While some in the field believe MSCs can become cells that secrete insulin, MSCs may help reduce glucose levels through MSC-secreted paracrine factors. The most optimal results to date appear to involve co-transplantation of β-cells and MSCs. Transplantation of MSCs in humans for a variety of conditions has been generally well tolerated, although results have been variable as a function of delivery route, and the variability in potency of cells between donors, tissue sources, and culture conditions has been well documented.